Soligenix (SNGX) Operating Expenses (2010 - 2026)
Soligenix's (SNGX) quarterly Operating Expenses came in at $2.9 million in Q1 2026, down 4.68% YoY from $3.0 million in Q1 2025, and down 16.97% on a QoQ basis from $3.5 million in Q4 2025.
Soligenix (SNGX) Operating Expenses (2010 - 2026) Analysis & Trends
Soligenix (SNGX) has 17 years of Operating Expenses data on file, last reported at $2.9 million in Q1 2026.
- Quarterly Operating Expenses fell 4.68% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.7 million (up 13.09% YoY) and the FY2025 annual result came in at $11.8 million, up 25.49% from the prior year.
- Operating Expenses slipped to $2.9 million in Q1 2026, from $3.5 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $4.3 million in Q1 2022 to a low of $1.7 million in Q2 2023.
- A 5-year average of $2.7 million and a median of $2.8 million in 2025 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses jumped 89.84% — and 2023, when it tumbled 51.81%.
- Tracing SNGX's Operating Expenses over 5 years: stood at $3.8 million in 2022, then sank by 43.13% to $2.2 million in 2023, then jumped by 71.78% to $3.7 million in 2024, then retreated by 6.41% to $3.5 million in 2025, then slipped by 16.97% to $2.9 million in 2026.
- The last three Operating Expenses figures came in at $2.9 million (Q1 2026), $3.5 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 541.02 Mn |
| 10 | Soligenix | 6.32 Mn | 6.32 Mn | - | 2.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.10 Mn |
| Mar 31, 2026 | 2.88 Mn |
| Dec 31, 2025 | 3.47 Mn |
| Sep 30, 2025 | 2.58 Mn |
| Jun 30, 2025 | 2.76 Mn |
| Mar 31, 2025 | 3.03 Mn |
| Dec 31, 2024 | 3.71 Mn |
| Sep 30, 2024 | 1.87 Mn |
| Jun 30, 2024 | 1.74 Mn |
| Mar 31, 2024 | 2.12 Mn |
| Dec 31, 2023 | 2.16 Mn |
| Sep 30, 2023 | 1.80 Mn |
| Jun 30, 2023 | 1.65 Mn |
| Mar 31, 2023 | 2.18 Mn |
| Dec 31, 2022 | 3.80 Mn |
| Sep 30, 2022 | 3.12 Mn |
| Jun 30, 2022 | 3.43 Mn |
| Mar 31, 2022 | 4.29 Mn |
| Dec 31, 2021 | 4.55 Mn |
| Sep 30, 2021 | 3.38 Mn |